Physician profile
Cynthia P Butler
NPI 1487668000
$1,535.56
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $215 · 2021: $30.51 · 2022: $33.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $522.37 | 2019-2020 | |
| Novo Nordisk INC | $273.45 | 2019 | |
| Amgen INC. | $141.02 | 2019-2020 | |
| Lilly USA, LLC | $138.43 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.59 | 2019-2020 | |
| Abbvie INC. | $64.43 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $54.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.77 | 2019 | |
| Pfizer INC. | $39.40 | 2020 | |
| Glaxosmithkline, LLC. | $34.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.34 | 2019 | |
| Abbott Laboratories | $19.60 | 2019 | |
| Amarin Pharma, INC. | $18.67 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $13.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.93 | 2019 | |
| Allergan, INC. | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.